SCHEMBL2977455

SCHEMBL2977455

COC(=O)c1sc(N)cc1O[C@H](C)c1ccccc1C(F)(F)F

nearest known ligand 0.49

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 18/20 0.49
PLK3 Q9H4B4 10/20 0.49
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 1/20 0.46
NEK2 P51955 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30426721 1.00 PLK1 (0.49) PLK1PLK3CYP3A4CYP2C9NEK2
SCHEMBL25267168 1.00 PLK1 (0.49) PLK1PLK3CYP3A4CYP2C9NEK2
Hydrochloric Acid SCHEMBL3118930 0.99 PLK1 (0.49) PLK1PLK3CYP3A4CYP2C9NEK2
SCHEMBL2991160 0.89 PLK1 (0.50) PLK1PLK3CYP3A4CYP2C9NEK2
SCHEMBL13440166 0.86 PLK1 (0.47) PLK1PLK3CYP3A4CYP2C9NEK2
SCHEMBL2987886 0.83 PLK1 (0.45) PLK1PLK3CYP3A4CYP2C9NEK2
SCHEMBL3264657 0.83 PLK1 (0.45) PLK1PLK3CYP3A4CYP2C9NEK2
SCHEMBL4552924 0.83 PLK1 (0.48) PLK1PLK3CYP3A4CYP2C9
SCHEMBL2973598 0.83 PLK1 (0.48) PLK1PLK3CYP3A4CYP2C9
SCHEMBL20108162 0.81 KMT2A (0.48) PLK1PLK3NEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236954-B2 Processes for preparing benzimidazole thiophenes GLAXOSMITHKLINE LLC (US) 2012-08-07 US claimed
US-20100256376-A1 Processes For Preparing Benzimidazole Thiophenes GLAXOSMITHKLINE LLC 2010-10-07 US claimed
EP-2170871-A2 PROCESSES FOR PREPARING BENZIMIDAZOLE THIOPHENES GlaxoSmithKline LLC (US) 2010-04-07 EP claimed
WO-2009002916-A2 PROCESSES FOR PREPARING BENZIMIDAZOLE THIOPHENES SMITHKLINE BEECHAM CORPORATION (US) 2008-12-31 WO claimed
US-12403198-B2 Benzimidazole thiophene derivative compounds inducing selective degradation of PLK1 UPPTHERA (KR) 2025-09-02 US disclosed
US-20230159515-A1 BENZIMIDAZOLE THIOPHENE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1 UPPTHERA (KR) 2023-05-25 US disclosed
US-20230159515-A1 BENZIMIDAZOLE THIOPHENE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1 UPPTHERA (KR) 2023-05-25 US disclosed
US-20230159515-A1 BENZIMIDAZOLE THIOPHENE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1 UPPTHERA (KR) 2023-05-25 US disclosed
US-8236954-B2 Processes for preparing benzimidazole thiophenes GLAXOSMITHKLINE LLC (US) 2012-08-07 US disclosed
US-8236954-B2 Processes for preparing benzimidazole thiophenes GLAXOSMITHKLINE LLC (US) 2012-08-07 US disclosed
US-8236954-B2 Processes for preparing benzimidazole thiophenes GLAXOSMITHKLINE LLC (US) 2012-08-07 US disclosed
US-20100256376-A1 Processes For Preparing Benzimidazole Thiophenes GLAXOSMITHKLINE LLC 2010-10-07 US disclosed
EP-1922316-A1 BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK MODULATORS SmithKline Beecham Corporation (US) 2008-05-21 EP disclosed
US-20070270437-A1 Benzimidazole Thiophene Compounds CHEUNG MUI 2007-11-22 US disclosed
US-20070270437-A1 Benzimidazole Thiophene Compounds CHEUNG MUI 2007-11-22 US disclosed
US-20070270437-A1 Benzimidazole Thiophene Compounds CHEUNG MUI 2007-11-22 US disclosed
WO-2007030359-A1 BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK MODULATORS SMITHKLINE BEECHAM CORPORATION (US) 2007-03-15 WO disclosed
WO-2007030361-A2 BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-03-15 WO disclosed
WO-2007030366-A1 REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES SMITHKLINE BEECHAM CORPORATION (US) 2007-03-15 WO disclosed
WO-2007030366-A1 REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES SMITHKLINE BEECHAM CORPORATION (US) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256376-A1 Processes For Preparing Benzimidazole Thiophenes TPMT, TBKBP1, TYMP PLK1 735/4885PLK3 982/4885CYP3A4 12/4885
US-20070270437-A1 Benzimidazole Thiophene Compounds ABCB1, CYP3A5, ABCG2 PLK1 458/4885PLK3 1235/4885CYP3A4 4/4885
US-20230159515-A1 BENZIMIDAZOLE THIOPHENE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1 PLK1, BUB1, BUB1B PLK1 1/4885PLK3 18/4885CYP3A4 2686/4885
US-12403198-B2 Benzimidazole thiophene derivative compounds inducing selective degradation of PLK1 PLK1, BUB1, BUB1B PLK1 1/4885PLK3 18/4885CYP3A4 2686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.